Overview

Coxsackie Virus A21 Administered Intravenously (IV) for Solid Tumour Cancers (PSX-X04)

Status:
Completed
Trial end date:
2012-01-12
Target enrollment:
Participant gender:
Summary
Coxsackie A21 (CVA21) virus is to be administered by IV infusion to patients with Stage 4 melanoma, prostate and breast cancer. This is a dose escalation, safety study.
Phase:
Phase 1
Details
Lead Sponsor:
Viralytics